PMID: 16639170Apr 28, 2006Paper

Treatment-refractory schizophrenia

Current Opinion in Psychiatry
Peter F Buckley, Nitin Shendarkar

Abstract

The aim of this article is to critically review the current literature on treatment-refractory schizophrenia with an emphasis on emergent themes and key findings. New information continues to emerge on the impact of each second-generation antipsychotic on the treatment-refractory patient population and on the traditionally more difficult-to-treat components (e.g. cognition, suicidality, violence) of the illness. There are continued efforts with pharmacogenetics to predict response and side-effect risk with antipsychotic medications. Polypharmacy continues to be a major and poorly understood treatment practice. Our field is advancing the therapeutic nuances of therapy with second-generation antipsychotics in treatment-refractory schizophrenia. Additionally, there is a growing appreciation of the emergent adverse-effect profile of antipsychotic medications and these risk-benefit considerations are more pronounced in severely ill patients.

References

Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·R ShilohA Weizman
Jan 7, 2003·Archives of General Psychiatry·Herbert Y MeltzerUNKNOWN International Suicide Prevention Trial Study Group
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Istvan BitterUNKNOWN Olanzapine HGCK Study Group
Jan 8, 2004·Journal of Clinical Psychopharmacology·Edmund P HarriganMichelle Middle
Jan 21, 2004·The International Journal of Neuropsychopharmacology·Stefan BenderMarkus Gastpar
Jan 21, 2004·Biological Psychiatry·Uriel Heresco-LevyDaniel C Javitt
Jan 30, 2004·Pharmacopsychiatry·R M Procyshyn, B Thompson
Feb 3, 2004·The American Journal of Psychiatry·Alan S BellackYe Yang
Feb 18, 2004·Current Medicinal Chemistry·C Simon SebastianPeter F Buckley
Mar 3, 2004·European Archives of Psychiatry and Clinical Neuroscience·Norbert MüllerMichael Riedel
Mar 6, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Leslie CitromeKatherine A Tracy
Mar 27, 2004·The International Journal of Neuropsychopharmacology·Robin Emsley, Piet Oosthuizen
Apr 6, 2004·Schizophrenia Research·Peter F BuckleyRobin A Emsley
Apr 6, 2004·Schizophrenia Research·Brian B SheitmanJeffrey A Lieberman
Apr 6, 2004·Schizophrenia Research·Kimberly H LittrellCraig G Johnson
Apr 6, 2004·The Psychiatric Clinics of North America·Laura A Flashman, Michael F Green
Apr 7, 2004·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Harpreet S Duggal
Apr 16, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Danielle C TurnerBarbara J Sahakian
Apr 20, 2004·Clinical Neuropharmacology·Murray H Rosenthal, Sharon L Bryant
Apr 30, 2004·CNS Spectrums·Zeinab Abdi, Tonmoy Sharma
Apr 30, 2004·CNS Spectrums·Joseph I FriedmanJack M Gorman
May 1, 2004·Journal of Clinical Psychopharmacology·Michael A ReveleyUNKNOWN RIS-GBR-31 Investigators
May 4, 2004·The Journal of Clinical Psychiatry·Alexander L MillerBernardo Tarin-Godoy
May 4, 2004·The Journal of Clinical Psychiatry·Jean-Pierre LindenmayerMiranda Chakos
May 4, 2004·The American Journal of Psychiatry·Marcus W AgelinkIsmail Ak
May 13, 2004·The International Journal of Neuropsychopharmacology·Donald C Goff, Oliver Freudenreich
May 13, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Josette G HarrisRobert Freedman
May 19, 2004·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Doron MazehAbraham Weizman
May 28, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael PoyurovskyAbraham Weizman

❮ Previous
Next ❯

Citations

Nov 14, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanUNKNOWN MEM-MD-29 Study Group
Aug 28, 2007·The Psychiatric Clinics of North America·Helio Elkis
Feb 22, 2012·The International Journal of Neuropsychopharmacology·Catherine FrogleyMarco Picchioni
Dec 31, 2009·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Gin MalhiGarry Walter
Jan 31, 2017·The International Journal of Social Psychiatry·Anna-Lena NordstroemJustine Lalonde
Dec 16, 2006·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Philippe HugueletManuela Etter

❮ Previous
Next ❯

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here